Skip to main content
Deborah Friedman, MD, Pediatric Cardiology, Valhalla, NY, Westchester Medical Center

DeborahMFriedmanMD

Pediatric Cardiology Valhalla, NY

Professor of Pediatrics, New York Medical College

Dr. Friedman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Friedman's full profile

Already have an account?

  • Office

    New York Medical College, Pediatric Cardiology
    40 Sunshine Cottage Rd
    Valhalla, NY 10595
    Phone+1 914-594-2222
    Fax+1 914-594-2221
  • Is this information wrong?

Education & Training

  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineFellowship, Pediatric Cardiology, 1980 - 1983
  • Jacobi Medical Center/Albert Einstein College of Medicine
    Jacobi Medical Center/Albert Einstein College of MedicineResidency, Pediatrics, 1977 - 1980
  • University of Chicago Division of the Biological Sciences The Pritzker School of Medicine
    University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1977

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1978 - 2025
  • NJ State Medical License
    NJ State Medical License 1990 - 2025
  • American Board of Pediatrics Pediatrics
  • American Board of Pediatrics Pediatric Cardiology

Awards, Honors, & Recognition

  • Top Doctors: New York Metro Area Castle Connolly, 2002-2014
  • Westchester Magazine: Top Doctors Castle Connolly, 2010-2013
  • New York Magazine: Top Doctors Castle Connolly, 2005-2008
  • Join now to see all

Publications & Presentations

PubMed

Press Mentions

  • Zosano Pharma Corporation (NASDAQ: ZSAN) Soars 171% After Final Milestone Completed in Long-Term Safety Study of Qtrypta, a Acute Treatment for Migraine Disease
    Zosano Pharma Corporation (NASDAQ: ZSAN) Soars 171% After Final Milestone Completed in Long-Term Safety Study of Qtrypta, a Acute Treatment for Migraine DiseaseFebruary 21st, 2019

Professional Memberships

Hospital Affiliations